Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 17;10(1):1888488.
doi: 10.1080/2162402X.2021.1888488.

Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer

Elise F Nassif  1 , Constance Thibault  1   2 , Stéphane Oudard  1   2 , Jérôme Galon  3   4   5
Affiliations
Review

Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer

Elise F Nassif et al. Oncoimmunology. .

Abstract

This review details the clinical utility of Immunoscore, measuring the immune response to cancer within the tumor microenvironment, in bladder cancer. Immunoscore was recently introduced into ESMO Clinical Practice Guidelines for gastrointestinal cancer and into the WHO classification of the Digestive System Tumors. In muscle-invasive bladder cancer (MIBC), the standard-of-care treatment is neo-adjuvant chemotherapy and cystectomy. However, only 50% of the patients are still alive at 5 years. The degree of histologic response positively correlated with Immunoscore and patients at lower risk of relapse or death were associated with a high-Immunoscore. Immunoscore is also predicting response to neoadjuvant chemotherapy-based treatment in several indications. This paves the way for the use of Immunoscore in clinical practice not only in gastrointestinal tumors but also in bladder cancer, and beyond.

Keywords: Immunoscore; MIBC; bladder cancer; cancer classification; chemotherapy; immunity; immuno-oncology; neoadjuvant; predictive; prognosis; surgery; tumor microenvironment.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Illustration of a precision immunoscore-based neoadjuvant treatment approach
See this image and copyright information in PMC

References

    1. Vale CL, Collaboration ABCAM-A.. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202–3. doi:10.1016/j.eururo.2005.04.006. - DOI - PubMed
    1. Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020. doi:10.1038/s41568-020-0285-7. - DOI - PubMed
    1. Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity. 2020;52:55–81. doi:10.1016/j.immuni.2019.12.018. - DOI - PubMed
    1. Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, Botti G, Marincola FM, Ciliberto G, Pages F, Ascierto PA, et al. Immunoscore and immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J Transl Med. 2016;14:273. doi:10.1186/s12967-016-1029-z. - DOI - PMC - PubMed
    1. Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pages F. Rational bases for the use of the immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol. 2016;28:373–382. doi:10.1093/intimm/dxw021. - DOI - PMC - PubMed

Publication types

LinkOut - more resources